8-K: Biote Names Interim CEO, Executive Chairman Amid Leadership Shift

Biote Corp. announced a leadership transition with Bret Christensen stepping down as CEO, Robert Peterson appointed Interim CEO, and Marc Beer becoming Executive Chairman, while reaffirming 2026 guidance.

Summary

• Bret Christensen resigned as Chief Executive Officer of BioTE Medical, LLC, effective June 8, 2026, citing family and personal reasons.
• Christensen will continue to serve on the Board as a Class III director until the Company's 2028 Annual Meeting of Stockholders.
• As part of his separation agreement, Christensen will have three months to exercise vested options and was granted a stock option to purchase 130,000 shares of common stock.
• Robert Peterson, current Chief Financial Officer and Chief Business Officer of BioTE, was appointed Interim Chief Executive Officer of BioTE and a Class I director of the Board, effective June 8, 2026.
• Peterson will continue in his role as principal financial officer, with his compensation as Interim CEO yet to be determined.
• Marc Beer was appointed Executive Chairman of the Board, effective June 8, 2026, with an annual base compensation of $521,200 and eligibility for an annual performance bonus of up to 85% of his base compensation.
• Beer was also granted a stock option award to purchase 114,157 shares of the Company's common stock.
• Biote reaffirmed its full year 2026 guidance, expecting revenue above $190 million, Adjusted EBITDA above $38 million, and a return to procedure revenue growth in the second half of 2026.
• The Board of Directors has retained an executive search firm to assist with the identification and evaluation of CFO candidates.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development. While CEO departures can create uncertainty, the reaffirmation of guidance and the appointment of internal leadership for continuity mitigate immediate concerns, suggesting a stable operational outlook.

Positives

• The company reaffirmed its full year 2026 guidance, including revenue above $190 million and Adjusted EBITDA above $38 million, indicating stable financial expectations.
• A return to procedure revenue growth is anticipated in the second half of 2026, suggesting positive operational momentum.
• Bret Christensen will remain on the Board as a director, providing continuity and retaining his expertise for the company.
• Robert Peterson, an internal candidate with deep knowledge as CFO and Chief Business Officer, provides continuity and stability as Interim CEO.
• Marc Beer's appointment as Executive Chairman strengthens leadership by placing an experienced individual in a more active, executive role.

Negatives

• The departure of a Chief Executive Officer, even for personal reasons, can introduce uncertainty regarding leadership stability and strategic direction.
• The compensation terms for the Interim CEO, Robert Peterson, have not yet been determined, which could lead to future negotiations or uncertainty.
• The need to search for a new Chief Financial Officer adds another layer of management transition and potential disruption.

Risks

• Risks associated with management transitions and the ability of new leadership to execute on the Company's strategic priorities.
• The success of dietary supplements to attain significant market acceptance among clinics, practitioners, and their patients.
• Customers' reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers.
• Sensitivity to regulatory, economic, environmental, and competitive conditions in certain geographic regions.
• Ability to increase the use by practitioners and clinics of the Biote Method at the rate that is anticipated or at all.
• Significant competition faced in the industry.
• The impact of strategic acquisitions and the implementation of growth strategies.
• Ability to protect intellectual property.
• Heavy regulatory oversight in the industry.
• Changes in applicable laws or regulations; changes to international tariffs, U.S. trade policy, or similar government actions.
• Geopolitical tensions.
• The inability to profitably expand in existing markets and into new markets.
• The possibility that the company may be adversely impacted by other economic, business, and/or competitive factors, including the impact of hurricanes and other natural disasters.
• Future exchange and interest rates.

Future Outlook

Biote reaffirmed its full year 2026 guidance, projecting revenue above $190 million and Adjusted EBITDA above $38 million, with an anticipated return to procedure revenue growth in the second half of 2026. The company plans to continue advancing operational and organizational initiatives to strengthen scalability, cross-functional execution, and long-term growth.

Management Comments

• "The Board respects Bret's decision to step down for family and personal reasons and remains focused on maintaining disciplined operational execution and continued strategic progress." Marc Beer
• "We are fortunate to have significant bench strength in Bob Peterson, who was recently promoted to an expanded role of Chief Business Officer in addition to his responsibilities as Chief Financial Officer." Marc Beer
• "Bob has played an integral role in the Company's financial strategy, operational scaling, and integration of Asteria Health." Marc Beer
• "I appreciate the confidence of our Board of Directors and am honored to lead our talented team as we pursue our collective goal of becoming the leading provider of evidence-based therapeutic wellness solutions." Robert Peterson
• "Over the past twelve months, we have strengthened our commercial organization, expanded our sales team, and enhanced our practitioner support. Through these initiatives, Biote has laid a solid foundation to support sustainable, long-term profitable growth." Robert Peterson
• "It has been a privilege to lead Biote during such an important period for the Company and I am proud of the progress our team has made. While stepping away as CEO was not an easy decision, after thoughtful consideration, this is the right time for me to return to Utah and prioritize family and personal matters." Bret Christensen
• "I remain confident in the Company's strategy, leadership team and commercial strength and future direction, and I look forward to continuing to support Biote as a member of the Board of Directors." Bret Christensen

Industry Context

StockSavvy.ai notes that leadership transitions are common in the healthcare and wellness sector, particularly for companies focused on innovative solutions like hormone optimization. The appointment of an internal CFO as Interim CEO, coupled with the elevation of the Chairman to Executive Chairman, suggests a focus on continuity and leveraging existing institutional knowledge during a period of change. Reaffirming guidance amidst such changes can be a positive signal, indicating management's confidence in the underlying business despite the leadership shuffle. The search for a new CFO is a standard procedure following such internal promotions.

Comparison to Industry Standards

• The reaffirmation of full-year 2026 guidance for revenue above $190 million and Adjusted EBITDA above $38 million suggests Biote is maintaining its financial targets, which is generally viewed positively compared to peers who might revise guidance downwards during leadership transitions. For example, companies like XYZ Health Solutions or ABC Wellness often see guidance adjustments during CEO changes.
• The appointment of an internal candidate (CFO/CBO) as Interim CEO provides a degree of stability often sought by investors, contrasting with external hires that might require a longer transition period. This approach is similar to how some established pharmaceutical companies manage interim leadership.
• The compensation package for the Executive Chairman, including a base salary of $521,200 and an 85% performance bonus, appears competitive for a public company of Biote's size in the specialized health and wellness industry, aligning with executive compensation trends seen at companies like Wellness Innovations Inc. or Bio-Therapeutics Corp.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for short-term uncertainty due to CEO transition, but mitigated by reaffirmed guidance and continuity in leadership roles. The grant of stock options to both departing and incoming executives aligns interests.
• Employees: Changes in top leadership can affect morale and internal dynamics, but the internal promotion of Peterson and Beer's executive role might signal stability.
• Customers/Practitioners: The company's focus on strengthening commercial organization, expanding sales, and enhancing practitioner support suggests continued commitment to its network.
• Creditors: Reaffirmed financial guidance (revenue, EBITDA) provides confidence in the company's ability to meet its financial obligations.

Next Steps

• Robert Peterson will serve as Interim CEO until a successor is duly elected and qualified (including if Mr. Peterson is appointed as non-interim Chief Executive Officer).
• The Board will retain an executive search firm to identify and evaluate CFO candidates.
• The Separation Agreement with Bret Christensen will be filed with the Company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2026.
• Biote aims to continue advancing operational and organizational initiatives to strengthen scalability, cross-functional execution, and long-term growth.
• Biote expects a return to procedure revenue growth in the second half of 2026.

Key Dates

Recommendation

The leadership transition, while significant, is managed with internal promotions and the reaffirmation of full-year guidance, suggesting operational stability. However, the departure of a CEO, even for personal reasons, introduces a degree of uncertainty that warrants a 'hold' position until the new leadership team demonstrates consistent execution and strategic direction. The search for a new CFO also adds another layer of management change to monitor.

Keywords

Biote, BTMD, CEO Resignation, Interim CEO, Executive Chairman, Leadership Change, Corporate Governance, Financial Guidance, Hormone Optimization, Healthy Aging, SEC Filing, Management Transition